80 FR 59794 - Prospective Grant of Start-Up Exclusive License: Differential Expression of Molecules Associated With Acute Stroke

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 191 (October 2, 2015)

Page Range		59794-59794
FR Document		2015-24988

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive license to VuEssence, which is located in Florida, to practice the inventions embodied in the following patents:

Federal Register, Volume 80 Issue 191 (Friday, October 2, 2015)

[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Page 59794]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-24988]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive License: Differential 
Expression of Molecules Associated With Acute Stroke

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of a start-up 
exclusive license to VuEssence, which is located in Florida, to 
practice the inventions embodied in the following patents:

1. AU Patent 2005248410, issued August 5, 2010 (E-306-2003/0-AU-03)
2. US Patent 7,749,700, issued July 6, 2010 (E-306-2003/1-US-01)

    The patent rights in these inventions have been assigned to the 
United States of America. The prospective start-up exclusive license 
territory may be worldwide and the field of use may be limited to in 
vitro class III diagnostic device for the detection and assessment of 
ischemic stroke in humans.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 19, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated start-up 
exclusive evaluation option license should be directed to: Susan Ano, 
Ph.D., NINDS Technology Transfer and Development Branch, 31 Center 
Drive, Suite 8A52, MS2540, Bethesda, MD 20892; Telephone: (301) 435-
5515; Email: [email protected].

SUPPLEMENTARY INFORMATION: The present technology claims methods of 
determining whether a subject had an ischemic stroke by detecting 
expression of twenty biomarkers in the blood, comparing expression 
levels to an individual who has not had a stroke, and determining 
whether there was at least a four-fold increase in the biomarker 
expression levels. Each of the biomarkers is detectable by a specified 
set of sequences.
    The patent also claims a method of administering an appropriate 
treatment regimen for a subject who had an ischemic stroke.
    The prospective start-up exclusive license may be granted unless 
within fifteen (15) days from the date of this published notice, the 
NIH receives written evidence and argument that establishes that the 
grant of the license would not be consistent with the requirements of 
35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated start-up exclusive license. Comments and objections 
submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-24988 Filed 10-1-15; 8:45 am]
 BILLING CODE 4140-01-P

59794 Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices

Dated: September 28, 2015. Physiology, and Biological Chemistry ischemic stroke by detecting expression
Melanie J. Gray, Research; 93.862, Genetics and of twenty biomarkers in the blood,
Program Analyst, Office of Federal Advisory Developmental Biology Research; 93.88, comparing expression levels to an
Minority Access to Research Careers; 93.96,
Committee Policy.
Special Minority Initiatives, National
individual who has not had a stroke,
[FR Doc. 2015–24983 Filed 10–1–15; 8:45 am] Institutes of Health, HHS) and determining whether there was at
BILLING CODE 4140–01–P least a four-fold increase in the
Dated: September 28, 2015. biomarker expression levels. Each of the
Melanie J. Gray, biomarkers is detectable by a specified
DEPARTMENT OF HEALTH AND Program Analyst, Office of Federal Advisory set of sequences.
HUMAN SERVICES Committee Policy. The patent also claims a method of
[FR Doc. 2015–24984 Filed 10–1–15; 8:45 am] administering an appropriate treatment
National Institutes of Health BILLING CODE 4140–01–P regimen for a subject who had an
ischemic stroke.
National Institute of General Medical The prospective start-up exclusive
Sciences; Notice of Closed Meetings DEPARTMENT OF HEALTH AND license may be granted unless within
Pursuant to section 10(d) of the HUMAN SERVICES fifteen (15) days from the date of this
Federal Advisory Committee Act, as published notice, the NIH receives
amended (5 U.S.C. App.), notice is National Institutes of Health written evidence and argument that
hereby given of the following meetings. establishes that the grant of the license
Prospective Grant of Start-Up would not be consistent with the
The meetings will be closed to the Exclusive License: Differential
public in accordance with the requirements of 35 U.S.C. 209 and 37
Expression of Molecules Associated CFR part 404.
provisions set forth in sections With Acute Stroke
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Complete applications for a license in
as amended. The grant applications and AGENCY: National Institutes of Health, the field of use filed in response to this
the discussions could disclose HHS. notice will be treated as objections to
confidential trade secrets or commercial ACTION: Notice. the grant of the contemplated start-up
property such as patentable material, exclusive license. Comments and
and personal information concerning SUMMARY: This is notice, in accordance objections submitted to this notice will
individuals associated with the grant with 35 U.S.C. 209 and 37 CFR part 404, not be made available for public
applications, the disclosure of which that the National Institutes of Health inspection and, to the extent permitted
would constitute a clearly unwarranted (NIH), Department of Health and Human by law, will not be released under the
invasion of personal privacy. Services, is contemplating the grant of a Freedom of Information Act, 5 U.S.C.
start-up exclusive license to VuEssence, 552.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
which is located in Florida, to practice Dated: September 28, 2015.
Panel; Peer review of Support of Competitive the inventions embodied in the
Richard U. Rodriguez,
Research (SCORE) Applications. following patents:
Acting Director, Office of Technology
Date: October 27, 2015. 1. AU Patent 2005248410, issued Transfer, National Institutes of Health.
Time: 11:00 a.m. to 5:00 p.m. August 5, 2010 (E–306–2003/0–
Agenda: To review and evaluate grant [FR Doc. 2015–24988 Filed 10–1–15; 8:45 am]
AU–03)
applications. 2. US Patent 7,749,700, issued July 6, BILLING CODE 4140–01–P
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, 3An.18,
2010 (E–306–2003/1–US–01)
Bethesda, MD 20892 (Virtual Meeting). The patent rights in these inventions DEPARTMENT OF HEALTH AND
Contact Person: Shinako Takada, Ph.D., have been assigned to the United States HUMAN SERVICES
Scientific Review Officer, Office of Scientific of America. The prospective start-up
Review, National Institute of General Medical exclusive license territory may be National Institutes of Health
Sciences, National Institutes of Health, 45 worldwide and the field of use may be
Center Drive, Room 3An.12M, Bethesda, MD limited to in vitro class III diagnostic Government-Owned Inventions;
20892, 301–594–2704, Shinako.takada@
nih.gov. device for the detection and assessment Availability for Licensing
of ischemic stroke in humans.
Name of Committee: National Institute of AGENCY: National Institutes of Health,
General Medical Sciences Special Emphasis DATES: Only written comments and/or HHS.
Panel; Review of INBRE Research Grant applications for a license which are
ACTION: Notice.
Applications. received by the NIH Office of
Date: October 27, 2015. Technology Transfer on or before SUMMARY: The inventions listed below
Time: 1:00 p.m. to 4:00 p.m. October 19, 2015 will be considered. are owned by an agency of the U.S.
Agenda: To review and evaluate grant
ADDRESSES: Requests for copies of the Government and are available for
applications.
Place: National Institutes of Health, patent application, inquiries, comments, licensing in the U.S. in accordance with
Natcher Building, 45 Center Drive, 3An.12A, and other materials relating to the 35 U.S.C. 209 and 37 CFR part 404 to
Bethesda, MD 20892 (Telephone Conference contemplated start-up exclusive achieve expeditious commercialization
Call). evaluation option license should be of results of federally-funded research
Contact Person: Lee Warren Slice, Ph.D., directed to: Susan Ano, Ph.D., NINDS and development. Foreign patent
Scientific Review Officer, Office of Scientific Technology Transfer and Development applications are filed on selected
mstockstill on DSK4VPTVN1PROD with NOTICES

Review, National Institute of General Medical Branch, 31 Center Drive, Suite 8A52, inventions to extend market coverage
Sciences, National Institutes of Health, 45
MS2540, Bethesda, MD 20892; for companies and may also be available
Center Drive, Room 3An.12E, Bethesda, MD
20892, 301–435–0807, slicelw@mail.nih.gov. Telephone: (301) 435–5515; Email: for licensing.
(Catalogue of Federal Domestic Assistance
anos@mail.nih.gov. FOR FURTHER INFORMATION CONTACT:
Program Nos. 93.375, Minority Biomedical SUPPLEMENTARY INFORMATION: The Licensing information and copies of the
Research Support; 93.821, Cell Biology and present technology claims methods of U.S. patent applications listed below
Biophysics Research; 93.859, Pharmacology, determining whether a subject had an may be obtained by writing to the

VerDate Sep<11>2014 20:43 Oct 01, 2015 Jkt 238001 PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 E:\FR\FM\02OCN1.SGM 02OCN1

Document Created: 2015-12-15 08:45:22
Document Modified: 2015-12-15 08:45:22

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 19, 2015 will be considered.
FR Citation		80 FR 59794

80 FR 59794 - Prospective Grant of Start-Up Exclusive License: Differential Expression of Molecules Associated With Acute Stroke

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 191 (October 2, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health